Last reviewed · How we verify
raltegravir and cisplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
raltegravir and cisplatin (raltegravir and cisplatin) — New Mexico Cancer Research Alliance.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| raltegravir and cisplatin TARGET | raltegravir and cisplatin | New Mexico Cancer Research Alliance | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- raltegravir and cisplatin CI watch — RSS
- raltegravir and cisplatin CI watch — Atom
- raltegravir and cisplatin CI watch — JSON
- raltegravir and cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). raltegravir and cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/raltegravir-and-cisplatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab